Zhongguancun: Subsidiary Company Receives Acceptance for Norepinephrine Tablet Marketing Authorization Application

Zhongguancun Announcement: The company's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has recently received the "Acceptance Notification" issued by the National Medical Products Administration. The application for the registration and marketing authorization of Multinore Tablets for domestic production has been accepted, with acceptance numbers CYHS2601851 and CYHS2601850, classified as chemical drug category 4. This medication is suitable for patients with gout accompanied by hyperuricemia, and the original drug is the world's only approved selective URAT1 inhibitor, which has been approved for marketing in China as of December 2024.